2026 ASCO | INNOVENT PRESENTS LONG-TERM FOLLOW-UP RESULTS FROM THE POC STUDY OF IBI363 (TAK-928) (PD-1/IL-2Α-BIAS BISPECIFIC FUSION PROTEIN), SHOWING ROBUST SURVIVAL BENEFITS IN ADVANCED IMMUNOTHERAPY-RESISTANT NON-SMALL CELL LUNG CANCER

Reuters · 2d ago

Please log in to view news